XiaoMi-AI文件搜索系统
World File Search SystemBSoC
处方信息重点 这些重点不包括安全有效地使用 PLUVICTO 所需的所有信息。查看完整处方
VISION 研究评估了 PLUVICTO 在进展性 PSMA 阳性 mCRPC 患者中的安全性[见临床研究 (14)]。在随机分组的 831 名患者中，734 名患者接受了至少一剂随机治疗。患者至少接受一剂 PLUVICTO 7.4 GBq (200 mCi)，每 6 至 10 周给药一次，外加 BSoC (N = 529) 或单独接受 BSoC (N = 205)。对于接受 PLUVICTO 加 BSoC 治疗的患者，接受随机治疗的中位持续时间为 7.8 个月（范围，0.3 至 24.9）。在接受 PLUVICTO 加 BSoC 治疗的患者中，接受 PLUVICTO 的中位剂量为 5（范围，1 至 6）。PLUVICTO 的中位累积剂量为 37.5 GBq（范围，7.0 至 48.3）。对于接受 PLUVICTO 加 BSoC 治疗的患者，随访的中位持续时间为 14.8 个月。
单击此处
Vision是一项前瞻性，开放标签，随机，第三阶段试验，评估了先前至少使用一种ARPI和一两个类紫杉烷治疗的PSMA阳性MCRPC的患者的PLUVICTO®。随机分组（2：1），八百三十一（n = 831）患者每6周接受PLUVICTO®7.4GBQ（200 MCI），最多可容纳6剂6剂加上BSOC（n = 551）或单独使用BSOC（n = 280）。At a median follow-up of 20.9 months, PLUVICTO® plus BSoC significantly prolonged, as compared with BSoC, both alternate primary efficacy endpoints, imaging-based progression-free survival (median, 8.7 vs. 3.4 months; hazard ratio for progression or death, 0.40; 99.2% confidence interval [CI], 0.29 to 0.57; p <0.001）和总生存期（中位数为15.3 vs. 11.3个月；死亡危险比，0.62; 95％CI，0.52至0.74; p <0.001）。所有关键的次要终点（客观反应，疾病控制和有症状骨骼事件的时间）显着偏爱Pluvicto®。2
瑞士 - pluvicto
1L First-line 2L Second-line ADA Anti-drug antibody ADME Absorption, distribution, metabolism, elimination ADT Androgen deprivation therapy AE Adverse event ALT Alanine aminotransferase AST Aspartate aminotransferase API Active pharmaceutical ingredient ATC Anatomical Therapeutic Chemical Classification System AUC Area under the plasma concentration-time curve AUC 24小时给药间隔BMI体重指数BRCA BRCA BRCA BRCA BRCA BRCA BSC最佳护理BSOC BSOC BSOC最佳护理CI置信区间C最大观察到血浆/血清的血清cRPC cRPC cRPC cRPC cRPC耐药性 - 耐药前列腺p450 dcr p450 dcr ddi ddi ddi ddi ddi ddi ddi ddi ddi ddi ddii Electrocardiogram ECOG Eastern Cooperative Oncology Group EMA European Medicines Agency ERA Environmental risk assessment ESI-MS Electrospray ionisation ESMO European Society for Medical Oncology FDA Food and Drug Administration (USA) GC Gas chromatography GLP Good Laboratory Practice HPLC High-performance liquid chromatography IC/EC 50 Half-maximal inhibitory/effective concentration ICH International Council for Harmonisation ICP-MS Inductively Coupled Plasma Mass Spectrometry Ig Immunoglobulin INN International non-proprietary name ITT Intention-to-treat LoQ List of Questions MAH Marketing Authorisation Holder Max Maximum MCBS Magnitude of Clinical Benefit Scale mCRPC Metastatic castration-resistant prostate cancer mHNPC Metastatic hormone-naïve prostate cancer Min Minimum MRHD Maximum recommended human dose MS Mass spectrometry MTD Maximum tolerated dose不适用NAAD新型雄激素轴药物NCCN国家综合癌症网络
瑞士公共评估报告Pluvicto CA
1L First-line 2L Second-line ADA Anti-drug antibody ADME Absorption, distribution, metabolism, elimination ADT Androgen deprivation therapy AE Adverse event ALT Alanine aminotransferase AST Aspartate aminotransferase API Active pharmaceutical ingredient ATC Anatomical Therapeutic Chemical Classification System AUC Area under the plasma concentration-time curve AUC 24小时给药间隔BMI体重指数BRCA BRCA BRCA BRCA BRCA BRCA BSC最佳护理BSOC BSOC BSOC最佳护理CI置信区间C最大观察到血浆/血清的血清cRPC cRPC cRPC cRPC cRPC耐药性 - 耐药前列腺p450 dcr p450 dcr ddi ddi ddi ddi ddi ddi ddi ddi ddi ddi ddii Electrocardiogram ECOG Eastern Cooperative Oncology Group EMA European Medicines Agency ERA Environmental risk assessment ESI-MS Electrospray ionisation ESMO European Society for Medical Oncology FDA Food and Drug Administration (USA) GC Gas chromatography GLP Good Laboratory Practice HPLC High-performance liquid chromatography IC/EC 50 Half-maximal inhibitory/effective concentration ICH International Council for Harmonisation ICP-MS Inductively Coupled Plasma Mass Spectrometry Ig Immunoglobulin INN International non-proprietary name ITT Intention-to-treat LoQ List of Questions MAH Marketing Authorisation Holder Max Maximum MCBS Magnitude of Clinical Benefit Scale mCRPC Metastatic castration-resistant prostate cancer mHNPC Metastatic hormone-naïve prostate cancer Min Minimum MRHD Maximum recommended human dose MS Mass spectrometry MTD Maximum tolerated dose不适用NAAD新型雄激素轴药物NCCN国家综合癌症网络
人类生物学，健康与社会2024-2025
NS 2450 Social Science Perspectives on Food and Nutrition (3 cr) NS 4250 Nutrition Communications and Counseling (3 cr) NS 4450 / 6455 , AEM 4450 / 6455 Toward a Sustainable Global Food System: Food Policy for Developing Countries (3 cr) NS 4480 / 6480 Economics of Food and Malnutrition (3 cr) NS 4500 Public Health Nutrition (3 cr) NS 4570 / ECON 3910 Health, Poverty, and Inequality: A Global Perspective (3 cr) COMM 2850 Communication, Environment, Science, and Health (3 cr) COMM 4760 Population Health Communication (3 cr) GDEV / LSP 2200 Sociology of Health and Ethnic Minorities (3 cr) GDEV 3020 Political Ecologies of Health (3 cr) GDEV 3111 / BSOC 3111 / SOC 3130 / STS 3111 Sociology of Medicine (3 cr) HD 2180 Human Development: Adulthood and Aging (3 cr) HD 2300 Cognitive Development (3 cr) HD 2600 / PSYCH 2750 Introduction to Personality (3 cr) HD 3290 Self-Regulation Across the Life Span (3 cr) HD 3300 Developmental Psychopathology (3 cr) HD 3325 Theory and Practice of Contemporary Clinical Psychology (3 cr) HD 3490 The Science of Well Being (3 CR）HD 3620人类粘结（3 CR）HD 3700 / Psych 3250成人心理病理学（3 CR）HD 4600老年和姑息研究专业发展（1.5 CR）HD 4770 HD 4770精神病理学在文学（3 CR）PubPol 2350美国卫生保健系统（3 cr）Pubol Pubol Pubol（3 Cr）Pubol Pubol（3 Cr）（3 CR）Pubol（3 Cr）Pubol（3 Cr）（3 Cr）（3110） （PubPol以前是PAM）PubPol 3280人口健康基本原理（3 Cr）（PubPol以前为PAM）PubPol 3780 3780病态？比较世界各地的医疗保健系统（3 CR）（PubPol以前为PAM）PubPol 3870 /5870医疗保健中的经济评估（3 CR）（PubPol以前是PAM）PubPol 4280 / Econ 3710风险健康行为的经济学经济学（3 CR）（3 CR）（Pubpol以前的PAM）< / div> < / div）< / div> < / div>